Esperion Therapeutics (ESPR) Stock Forecast & Price Target

Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on bringing new medicines to patients with elevated LDL-C. Despite dependence on two key products, bempedoic acid tablet and bempedoic acid/ezetimibe combination tablet, we have a positive outlook on the company as it recently entered into a definitive acquisition agreement with Archimed, a healthcare-focused private equity fund, for a potential equity value of up to $1.1B. The company also has the potential for continued expansion and growth with its successful Nexletol/Nexlizet franchise and recently updated ACC/AHA guidelines. However, there is some risk associated with financing, as Esperion will need to secure additional capital for ongoing operations.

Esperion Therapeutics is a commercial-stage biopharmaceutical company that focuses on developing therapies for patients with elevated LDL-C. However, the company's heavy reliance on two products and limited resources make it vulnerable in the competitive cholesterol-lowering market. Despite a strategic value with a multiproduct opportunity, the acquisition by Archimed is expected to close in 3Q26, and with potential alternative buyers unlikely to emerge, we see limited upside potential in the stock for the near term.